Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)

Stopped The study was terminated due to satisfaction of post-marketing commitments

Conditions

• Hepatitis C, Chronic
• Hepacivirus

Interventions

• BIOLOGICAL: Boceprevir
• BIOLOGICAL: Narlaprevir
• BIOLOGICAL: Peginterferon alfa-2b
• DRUG: Ribavirin
• OTHER: Blood/Plasma Collection

Sponsor

Merck Sharp & Dohme LLC